# A Study of Donanemab (LY3002813) in Healthy Chinese Participants

> **NCT05533411** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Donanemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05533411
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-14
- **Primary completion:** 2023-01-05
- **Final completion:** 2023-01-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05533411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05533411, "A Study of Donanemab (LY3002813) in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05533411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*